Sign In
Buy AGEN
$7.00
+0.0400 (+0.575%)
At Close: Aug 10, 2026
Agenus (NASDAQ:AGEN) Stock Price Crosses Above 200 Day Moving Average – Here’s What Happened
04:13am, Tuesday, 14'th Apr 2026
Agenus Inc. (NASDAQ: AGEN - Get Free Report) passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $3.67 and traded as high as $4.30. Agenus share
Can Agenus (AGEN) Run Higher on Rising Earnings Estimates?
01:21pm, Friday, 03'rd Apr 2026
Agenus (AGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
All You Need to Know About Agenus (AGEN) Rating Upgrade to Strong Buy
01:01pm, Friday, 03'rd Apr 2026
Agenus (AGEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Agenus (AGEN) is a Top Momentum Stock for the Long-Term
10:50am, Friday, 03'rd Apr 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Has Agenus (AGEN) Outpaced Other Medical Stocks This Year?
10:40am, Friday, 03'rd Apr 2026
Here is how Agenus (AGEN) and Ensign Group (ENSG) have performed compared to their sector so far this year.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AACR2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that data from an investigator-initiated Phase II trial condu
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global ph
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
02:02am, Wednesday, 01'st Apr 2026
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
Head-To-Head Analysis: Agenus (NASDAQ:AGEN) and VivoSim Labs (NASDAQ:VIVS)
01:31am, Friday, 27'th Mar 2026
VivoSim Labs (NASDAQ: VIVS - Get Free Report) and Agenus (NASDAQ: AGEN - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies b
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its March Stakeholder Webcast focused on continue
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AACR26--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that preliminary results from an investigator-sponsored study evaluating b
Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates
09:35pm, Monday, 16'th Mar 2026
Agenus (AGEN) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of a loss of $1.27 per share. This compares to a loss of $2.04 per share a year ago.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN) today reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting progress for th
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs
07:30am, Tuesday, 10'th Mar 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has triggered the first $20 million contingent payment un
Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update
04:30pm, Wednesday, 04'th Mar 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Agenus--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its fourth quarter and year-e
